CTNM Contineum Therapeutics, Inc.
P/E
--
Forward P/E
--
Price/Sales
11.15
Beta
0.856
Div Yield
--
Market Cap
--
Company Analysis
Latest News
Contineum Therapeutics, Inc. Q3 2026 Earnings Preview: What Analysts Expect on November 05, 2026
Wall Street expects Contineum Therapeutics to report a Q3 loss of $0.45 per share on revenue of $5.65 million, with the stock currently trading near $9.56...
Contineum Therapeutics third quarter 2026 net loss widens to $18.7M with cash runway through 2029
Contineum Therapeutics reported a third quarter 2026 net loss of $18.7 million, or $0.49 per share, as the clinical-stage company ramped up R&D spending for...
Contineum Therapeutics, Inc. Q3 2026 Earnings Preview: What Analysts Expect on October 29, 2026
Contineum Therapeutics is expected to report a Q3 2026 loss of $0.45 per share on revenue of $5.65 million, with the stock currently trading near $8.35 against...